US stock futures muted with Jackson Hole, retail earnings on tap
USANA Health Sciences Inc (NYSE:USNA). shares have reached a 52-week low, dipping to $27.58, as the company faces a tumultuous market environment. According to InvestingPro data, the stock currently trades significantly below its analyst consensus target range of $36-65. This latest price point underscores a significant downturn for the health and nutrition company, which has seen its stock value decrease by 42.71% over the past year. Despite the decline, USANA maintains impressive gross profit margins of 81% and holds more cash than debt on its balance sheet. Investors are closely monitoring USANA’s performance, as the company navigates through the pressures of a competitive sector and broader economic headwinds that have impacted consumer spending in the wellness industry. The 52-week low serves as a critical marker for USANA, reflecting investor sentiment and the challenges that lie ahead for the company in its efforts to regain momentum. InvestingPro analysis suggests the stock is currently undervalued, with additional insights available in the comprehensive Pro Research Report covering this and 1,400+ other US equities.
In other recent news, USANA Health Sciences reported its fourth-quarter 2024 earnings, surpassing analyst expectations with an earnings per share (EPS) of $0.64, compared to the forecasted $0.49. Revenue for the quarter also exceeded estimates, coming in at $214 million against the anticipated $208.84 million. However, the company issued guidance for fiscal year 2025 that disappointed investors, with projected earnings ranging from $2.35 to $3.00 per share, falling short of the consensus estimate of $2.87. USANA’s revenue forecast for FY2025 was set between $920 million and $1 billion, which bracketed the consensus estimate of $934.5 million.
The company’s full-year financials for 2024 showed a 7% decline in net sales to $855 million, down from $921 million in 2023, and a 34% drop in net earnings to $42 million. Despite these challenges, USANA’s President and CEO, Jim Brown, expressed optimism about the company’s future, citing positive momentum in certain regions and the strategic acquisition of Hiya Health. The acquisition, which aims to bolster USANA’s presence in the children’s health market, is expected to contribute $145 to $160 million in net sales for 2025.
Looking ahead, USANA plans to launch over 20 new products in 2025 and focus on enhancing its direct selling model. The company also projects Hiya Health’s revenue to grow by 29-42% in the coming year. Analysts from firms such as D.A. Davidson and Sidoti have noted USANA’s strategic positioning and recent developments, although market conditions in China remain a challenge.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.